导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.18% | 1721/4773 |
| 近一周 | -2.54% | 2502/5462 |
| 近一月 | -5.01% | 2974/5421 |
| 近一季 | -8.92% | 3018/5209 |
| 近半年 | -6.80% | 3142/4920 |
| 近一年 | 6.84% | 1400/4366 |
| 近两年 | 67.96% | 1017/2954 |
| 近三年 | 34.18% | 893/2253 |
| 成立以来 | 84.41% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.75% 1190/4961 |
18.19% 1408/5312 |
- - |
- - |
| 2025 | 30.27% 1338/4813 |
2.08% 1470/3635 |
1.89% 2042/4076 |
24.24% 1486/4524 |
0.82% 1749/4813 |
| 2024 | 5.78% 1811/3463 |
-2.64% 1396/2808 |
-5.30% 1686/3014 |
15.56% 1683/3129 |
-0.72% 1508/3463 |
| 2023 | -5.88% 789/2656 |
7.58% 551/2280 |
-3.98% 989/2385 |
-4.61% 1177/2515 |
-4.48% 1055/2655 |
| 2022 | -17.94% 643/2207 |
-13.30% 728/1919 |
3.07% 1221/2016 |
-10.47% 409/2113 |
2.56% 899/2208 |
| 2021 | 16.32% 272/1822 |
-1.48% 497/1255 |
9.32% 565/1330 |
4.66% 328/1466 |
3.19% 463/1822 |
| 2020 | 20.89% 702/1250 |
-4.79% 382/1028 |
16.55% 430/1067 |
6.37% 848/1164 |
2.42% 988/1184 |
| 2019 | 25.31% 604/1092 |
30.69% 235/754 |
-9.97% 707/804 |
0.39% 519/850 |
6.09% 657/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.83% 361/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 嘉实中证500ETF联接C VS. 长安沪深300非周期A(740101) |